JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB125912

Rabbit monoclonal [H26-10] Anti-Human IgG1 H&L

Be the first to review this product! Submit a review

|

(2 Publications)

Recombinant secondary antibody suitable for ELISA. Cited in 2 publications.

View Alternative Names

Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1

2 Images
ELISA - Rabbit monoclonal [H26-10] Anti-Human IgG1 H&L (AB125912)
  • ELISA

Lab

ELISA - Rabbit monoclonal [H26-10] Anti-Human IgG1 H&L (AB125912)

Direct ELISA antibody dose-response curve using ab125912 between 0-1000 ng/ml. Antigen concentration of 1000 ng/mL. An alkaline phosphatase-conjugated goat anti-rabbit IgG (H+L) (1/2500) was used as the secondary antibody.

ELISA - Rabbit monoclonal [H26-10] Anti-Human IgG1 H&L (AB125912)
  • ELISA

Lab

ELISA - Rabbit monoclonal [H26-10] Anti-Human IgG1 H&L (AB125912)

Direct ELISA antibody dose-response curve using ab125912 between 0-1000 ng/ml. Antigen concentration of 1000 ng/mL. An alkaline phosphatase-conjugated goat anti-rabbit IgG (H+L) (1/2500) was used as the secondary antibody.

Key facts

Host species

Rabbit

Target species

Human

Target isotype

IgG1

Target specificity

Heavy & Light chains

Minimal cross-reactivity
Pre-adsorbed

No

Applications

ELISA

applications

Clonality

Monoclonal

Clone number

H26-10

Isotype

IgG

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

ab125912 is specific for Human IgG1, heavy and light chain. The antibody recognises Human IgG, IgG1 lambda, Fc and F(ab)2. ab125912 does not recognise IgG2 lambda, IgG3 kappa, IgG3 lambda, Human IgA or Human IgGM.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/1000", "notes":"<p></p>" } } }

Product details

Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.09% Sodium azide Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Product protocols

Target data

Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed : 20176268, PubMed : 22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed : 17576170, PubMed : 20176268). Mediates IgG effector functions on monocytes triggering ADCC of virus-infected cells.
See full target information IGHG1

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Journal of pharmaceutical sciences 113:72-84 PubMed37844759

2023

Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models.

Applications

Unspecified application

Species

Unspecified reactive species

Jun Wang,Ting Chen,Donna M Ruszaj,Donald E Mager,Robert M Straubinger

Aging and disease 15:245-258 PubMed37307820

2023

Single-Cell Atlas of Atherosclerosis Patients by Cytof: Circulatory and Local Immune Disorders.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaolong Ya,Hao Li,Peicong Ge,Yiqiao Xu,Zechen Liu,Zhiyao Zheng,Siqi Mou,Chenglong Liu,Yan Zhang,Rong Wang,Qian Zhang,Xun Ye,Wenjing Wang,Dong Zhang,Jizong Zhao
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com